⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1698490 | 0.82 | MAPT (0.33) | — | |
| SCHEMBL25791916 | 0.82 | — | — | |
| SCHEMBL12395195 | 0.79 | PIK3CD (0.33) | — | |
| SCHEMBL761343 | 0.77 | MAPT (0.33) | — | |
| SCHEMBL18650798 | 0.74 | SLC6A2 (0.38) | — | |
| SCHEMBL12932818 | 0.70 | TDP1 (0.37) | — | |
| SCHEMBL3053671 | 0.69 | LMNA (0.54) | — | |
| Hydrochloric Acid SCHEMBL10518771 | 0.68 | MEN1 (0.38) | — | |
| SCHEMBL1698558 | 0.68 | TOP2A (0.35) | — | |
| SCHEMBL17791200 | 0.68 | MAPT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| CN-103827116-B | As LP-PLA2the 2,3-glyoxalidine of inhibitor also [1,2-c] pyrimidine-5 (1H)-one compound | 葛兰素集团有限公司 | 2016-08-31 | — | — | CN | disclosed |
| US-8349873-B2 | Factor XA inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120088795-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8063077-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110118244-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118244-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100249117-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7767697-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7763608-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |